Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000123305 | SCV000166612 | likely benign | Multiple endocrine neoplasia, type 2 | 2024-01-30 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV001014049 | SCV001174708 | benign | Hereditary cancer-predisposing syndrome | 2022-01-27 | criteria provided, single submitter | clinical testing | This alteration is classified as benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. |
All of Us Research Program, |
RCV000123305 | SCV004815148 | likely benign | Multiple endocrine neoplasia, type 2 | 2023-12-13 | criteria provided, single submitter | clinical testing | |
Myriad Genetics, |
RCV004791274 | SCV005403655 | likely benign | Multiple endocrine neoplasia type 2A | 2024-08-12 | criteria provided, single submitter | clinical testing | This variant is considered likely benign. This variant has been observed at a population frequency that is significantly greater than expected given the associated disease prevalence and penetrance. |